+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Measured Changes in Cataract over Six Months: Sensitivity of the Nidek EAS-1000

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Lens opacities in 98 eyes from 63 consecutive outpatients with cataract were recorded by both retroillumination and Scheimpflug slit methods by one operator. This was repeated at 26 ± 1 weeks. Image analysis used the EAS-1000 software. Cortical and posterior subcapsular (PSC) cataracts were measured in retroillumination images as density more than 14 cct units below background density. Linear densitometry of white scattered light along the optical axis was measured for slit images by both peak density and mean density (‘area under the curve’). Retroillumination images showed no discernible change over 6 months (the regression coefficient being as for the intersession reliability). Half of the Scheimpflug slit images could not be analysed because overlying cortical changes masked the more posterior parts of the lens. The other 49 eyes showed a significant increase in nuclear white scatter after 6 months, with greater degrees of change occurring in those eyes with the greatest amount of nuclear cataract initially. This is reflected by the decreased intraclass correlation coefficient (R = 0.42). The area of lens showing greatest change was the anterior fetal nucleus. The Nidek EAS-1000 is able to detect changes over a 6-month period in nuclear density but not in cortical or PSC cataract. The rate of progression of nuclear white scatter increases as the lens opacity becomes more dense. The ability to detect change in cataract over 6 months has implications for epidemiological studies and for trials of anti-cataract drugs.

          Related collections

          Author and article information

          Ophthalmic Res
          Ophthalmic Research
          S. Karger AG
          11 December 2009
          : 28
          : Suppl 2
          : 32-36
          Department of Ophthalmology, Melbourne University, Melbourne, Vic, Australia
          267954 Ophthalmic Res 1996;28:32–36
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5


          Comment on this article